"OK TO ENTER"

/GC/ 12/06/2010

Applicant: Henrik Arnberg Serial No.: 10/599,753

Filed : July 25, 2007

Page : 2

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Attorney's Docket No. 15665-0010US1

Listing of Claims:

1-15. (Canceled)

16. (**Previously Presented**) A method for treating a mammal suffering from a periodontal

disease, comprising locally administering by injection in the proximity of the periodontal disease

a therapeutically effective amount of a therapeutic agent, said therapeutic agent consisting of one

or more granulocyte-macrophage-colony stimulating factor (GM-CSF) polypeptides.

17. (Canceled)

18. (Previously Presented) The method of claim 16, wherein the periodontal disease is

gingivitis or periodontitis.

19-20. (Canceled)

21. (Previously Presented) The method of claim 16, wherein the composition is

administered by injection through the mucosal lining of the gingiva or by application in a

periodontal pocket.

22. (Previously Presented) The method of claim 16, wherein said GM-CSF is present in

the composition in a unit dosage amount of 5 µg to 800 µg.

Attorney's Docket No. 15665-0010US1

Applicant: Henrik Arnberg Serial No.: 10/599,753 Filed: July 25, 2007

Page: 3

23. (Previously Presented) The method of claim 22, wherein the unit dosage amount is 50 μ g to 100 μ g.

24. (**Previously Presented**) The method of claim 16, wherein the composition is administered at intervals ranging from once a day to once every third week.

25. (**Previously Presented**) The method of claim 16, wherein the composition is administered a total of 1 to 3 times for a period of one week.

26-31. (Canceled)

32. (**Previously Presented**) The method of claim 16, wherein the composition is administered by injection into the alveolar mucosa.

33. (**Previously Presented**) The method of claim 16, wherein the composition is administered by injection into the sublingual mucosa.

34. (Canceled)

35. (**Previously Presented**) The method of claim 16, wherein the composition is administered by injection between the periosteum of the alveolar bone and the alveolar mucosa, and wherein a needle used for injection is inserted into a flexible oral mucosal region adjacent to the gingiva.

36. (Previously Presented) The method of claim 16, wherein the mammal is a human.

37-48. (Canceled)